Arsenic trioxide (ATO), a component of the traditional Chinese medicine arsenic sublimate, promotes apoptosis and induces leukemic cell differentiation. Combined with all-trans-retinotic acid (ATRA), ATO has become the first-line induction therapy in treating acute promyelocytic leukemia (APL). The most common side effects of ATO include hepatotoxicity, gastrointestinal symptoms, water-sodium retention, and nervous system damage. In this report, we present a rare side effect, rhabdomyolysis, in a 68-year-old female APL patient who was treated with ATO. After taking 10 mg ATO daily for 6 days, she presented shortness of breath, myodynia, elevated creatine kinase, and acute renal insufficiency. This report describes the first case of ATO-induced rhabdomyolysis.
. [J]. Frontiers of Medicine, 2017, 11(2): 284-286.
Haiyan He, Ran An, Jian Hou, Weijun Fu. Arsenic trioxide induced rhabdomyolysis, a rare but severe side effect, in an APL patient: a case report. Front. Med., 2017, 11(2): 284-286.
Zhang TD, Chen GQ, Wang ZG, Wang ZY, Chen SJ, Chen Z. Arsenic trioxide, a therapeutic agent for APL. Oncogene 2001; 20(49): 7146–7153 https://doi.org/10.1038/sj.onc.1204762
pmid: 11704843
3
Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, Coutré S, Dahlberg S, Ellison R, Warrell RP Jr. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19(18): 3852–3860
pmid: 11559723
4
Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, Kantarjian H. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006; 107(9): 3469–3473 https://doi.org/10.1182/blood-2005-10-4006
pmid: 16373661
5
Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostami S, Jahani M, Hosseini R, Mossavi A, Baybordi E, Khodabadeh A, Iravani M, Bahar B, Mortazavi Y, Totonchi M, Aghdami N. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol 2006; 17(1): 131–134 https://doi.org/10.1093/annonc/mdj019
pmid: 16227315
6
Fanton L, Duperret S, Guillaumée F, Miras A, Vallon JJ, Malicier D. Fatal rhabdomyolysis in arsenic trioxide poisoning. Hum Exp Toxicol 1999; 18(10): 640–641 https://doi.org/10.1191/096032799678839509
pmid: 10557017
Moscetti L, Nelli F, Ruggeri EM. Rhabdomyolysis from erlotinib: a case report. Tumori 2011; 97(3): 415–416
pmid: 21789026
9
Ruggeri EM, Cecere FL, Moscetti L, Doni L, Padalino D, Di Costanzo F. Severe rhabdomyolysis during sunitinib treatment of metastatic renal cell carcinoma: a report of two cases. Ann Oncol 2010; 21(9): 1926–1927 https://doi.org/DOI: 10.1093/annonc/mdq395
pmid: 20729535
10
Quezada G, Kopp L, Estey E, Wells RJ. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia. Pediatr Blood Cancer 2008; 51(1): 133–135 https://doi.org/10.1002/pbc.21529
pmid: 18293388
Mendila M, Walter GF, Stoll M, Schmidt RE. Rhabdomyolysis in antiretroviral therapy with Lamivudin. Dtsch Med Wochenschr 1997; 122(33): 1003–1006 https://doi.org/10.1055/s-2008-1047721
pmid: 9296927
